The pharmaceutical companies behind Ozempic, Wegovy and other weight-loss meds push to prevent compounding pharmacies from ...

Eli Lilly and Company (NYSE: LLY) announced today that it has elected Jon Moeller as a new member of its board of directors ...

NEW YORK (Reuters) - About 44% of U.S. employers with 500 or more employees cover drugs for weight loss in 2024, up from 41% ...

Arguably, no big pharma stocks have dominated the industry more over the last few years than Eli Lilly (NYSE: LLY) and Pfizer ...

Old Town Med Spa is among those being accused of using false advertising and deceptive marketing practices to sell ...

Lilly to Develop Two Targets Identified and Validated Using ’ AI-Enabled, All-in-Human CONVERGE® Platform — Demonstration of ...

An update from Eli Lilly & Co ( (LLY) ) is now available.

Tuesday, November 19, 2024 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly ...

The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...

Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop ...

Analyst David Risinger of Leerink Partners reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), retaining the price target of ...

The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.